UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Direct regulation of CLOCK expression by REV-ERB

PloS one, 2011-03, Vol.6 (3), p.e17290-e17290

2011

Volltextzugriff (PDF)

REV-ERB agonism improves liver pathology in a mouse model of NASH

PloS one, 2020-10, Vol.15 (10), p.e0236000

2020

Volltextzugriff (PDF)

Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery

Molecular pharmacology, 2013-01, Vol.83 (1), p.1-8

2013

Volltextzugriff (PDF)

Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice

Gastroenterology (New York, N.Y. 1943), 2018-04, Vol.154 (5), p.1449-1464.e20

2018

Volltextzugriff (PDF)

Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease

Biochemical and biophysical research communications, 2016-10, Vol.479 (3), p.424-428

2016

Volltextzugriff (PDF)

Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis

Cancer cell, 2015-07, Vol.28 (1), p.42-56

2015

Volltextzugriff (PDF)

Structural basis of synthetic agonist activation of the nuclear receptor REV-ERB

Nature communications, 2022-11, Vol.13 (1), p.7131-7131, Article 7131

2022

Volltextzugriff (PDF)

Suppression of atherosclerosis by synthetic REV-ERB agonist

Biochemical and biophysical research communications, 2015-05, Vol.460 (3), p.566-571

2015

Volltextzugriff (PDF)

International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands

Pharmacological reviews, 2014-10, Vol.66 (4), p.918-947

2014

Volltextzugriff (PDF)

Recent Advances in the Medicinal Chemistry of Liver X Receptors

Journal of medicinal chemistry, 2018-12, Vol.61 (24), p.10935-10956

2018

Volltextzugriff (PDF)

Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases

Frontiers in medicine, 2023-02, Vol.10, p.1102469-1102469

2023

Volltextzugriff (PDF)

Disrupting the key circadian regulator CLOCK leads to age-dependent cardiovascular disease

Journal of molecular and cellular cardiology, 2017-04, Vol.105, p.24-37

2017

Volltextzugriff (PDF)

Distinct roles for REV-ERBα and REV-ERBβ in oxidative capacity and mitochondrial biogenesis in skeletal muscle

PloS one, 2018-05, Vol.13 (5), p.e0196787

2018

Volltextzugriff (PDF)

Rev-erbα heterozygosity produces a dose-dependent phenotypic advantage in mice

PloS one, 2020-05, Vol.15 (5), p.e0227720-e0227720

2020

Volltextzugriff (PDF)

DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex

Nature structural & molecular biology, 2011-05, Vol.18 (5), p.556-563

2011

Volltextzugriff (PDF)

A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis

PloS one, 2021-03, Vol.16 (3), p.e0249316

2021

Volltextzugriff (PDF)

Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression

PloS one, 2016-03, Vol.11 (3), p.e0151014-e0151014

2016

Volltextzugriff (PDF)

How to Make Glucocorticoids Safer

The Journal of pharmacology and experimental therapeutics, 2024-03, Vol.388 (3), p.748-750

Burris, Thomas P

2024

Volltextzugriff (PDF)

Pharmacological targeting of the mammalian clock reveals a novel analgesic for osteoarthritis-induced pain

Gene, 2018-05, Vol.655, p.1-12

2018

Volltextzugriff (PDF)

Regulation of p53 stability and apoptosis by a ROR agonist

PloS one, 2012-04, Vol.7 (4), p.e34921

2012

Volltextzugriff (PDF)

Identification of SR8278, a Synthetic Antagonist of the Nuclear Heme Receptor REV-ERB

ACS chemical biology, 2011-02, Vol.6 (2), p.131-134

2011

Volltextzugriff (PDF)

Targeting Th17‐IL‐17 Pathway in Prevention of Micro‐Invasive Prostate Cancer in a Mouse Model

The Prostate, 2017-06, Vol.77 (8), p.888-899

2017

Volltextzugriff (PDF)

Restoration of the molecular clock is tumor suppressive in neuroblastoma

Nature communications, 2021-06, Vol.12 (1), p.4006-4006, Article 4006

2021

Volltextzugriff (PDF)

REV-ERB activation as a novel pharmacological approach for treating inflammatory pain

Frontiers in pharmacology, 2023-04, Vol.14, p.1171931-1171931

2023

Volltextzugriff (PDF)

A synthesis strategy for tetracyclic terpenoids leads to agonists of ERβ

Nature communications, 2019-06, Vol.10 (1), p.2448-2448, Article 2448

2019

Volltextzugriff (PDF)

1 – 25 von 314

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(296)
Mit Volltextzugriff
(265)

Publikationsform

Sprache

Englisch
(314)

Erscheinungsjahr

n.n

Thema

Science & Technology
(205)
Life Sciences & Biomedicine
(168)
Humans
(130)
Animals
(101)
Mice
(69)
Biochemistry & Molecular Biology
(54)
Ligands
(52)
Male
(45)
Female
(41)
Pharmacology & Pharmacy
(39)
Biological And Medical Sciences
(35)
Endocrinology & Metabolism
(30)
Mice, Inbred C57bl
(28)
Multidisciplinary Sciences
(28)
Receptors, Cytoplasmic And Nuclear - Metabolism
(27)
Gene Expression
(26)
Nuclear Receptor
(26)
Cells, Cultured
(22)
Dose-Response Relationship, Drug
(22)
Science & Technology - Other Topics
(22)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Direct regulation of CLOCK expression by REV-ERB

REV-ERB agonism improves liver pathology in a mouse model of NASH

Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery

Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice

Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease

Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis

Structural basis of synthetic agonist activation of the nuclear receptor REV-ERB

Suppression of atherosclerosis by synthetic REV-ERB agonist

International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands

Recent Advances in the Medicinal Chemistry of Liver X Receptors

Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases

Disrupting the key circadian regulator CLOCK leads to age-dependent cardiovascular disease

Distinct roles for REV-ERBα and REV-ERBβ in oxidative capacity and mitochondrial biogenesis in skeletal muscle

Rev-erbα heterozygosity produces a dose-dependent phenotypic advantage in mice

DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex

A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis

Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression

How to Make Glucocorticoids Safer

Pharmacological targeting of the mammalian clock reveals a novel analgesic for osteoarthritis-induced pain

Regulation of p53 stability and apoptosis by a ROR agonist

Identification of SR8278, a Synthetic Antagonist of the Nuclear Heme Receptor REV-ERB

Targeting Th17‐IL‐17 Pathway in Prevention of Micro‐Invasive Prostate Cancer in a Mouse Model

Restoration of the molecular clock is tumor suppressive in neuroblastoma

REV-ERB activation as a novel pharmacological approach for treating inflammatory pain

A synthesis strategy for tetracyclic terpenoids leads to agonists of ERβ

Suchergebnisse filtern